KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Change in Account Payables (2023 - 2025)

Biocryst Pharmaceuticals' Change in Account Payables history spans 5 years, with the latest figure at $35.4 million for Q4 2025.

  • For Q4 2025, Change in Account Payables rose 73.33% year-over-year to $35.4 million; the TTM value through Dec 2025 reached $57.8 million, up 291.19%, while the annual FY2025 figure was $57.8 million, 291.19% up from the prior year.
  • Change in Account Payables reached $35.4 million in Q4 2025 per BCRX's latest filing, up from $24.6 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $49.2 million in Q4 2023 to a low of -$47.1 million in Q1 2025.
  • Average Change in Account Payables over 3 years is $7.1 million, with a median of $19.4 million recorded in 2024.
  • The largest YoY upside for Change in Account Payables was 11022.87% in 2024 against a maximum downside of 63.7% in 2024.
  • A 3-year view of Change in Account Payables shows it stood at $49.2 million in 2023, then crashed by 58.54% to $20.4 million in 2024, then soared by 73.33% to $35.4 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Change in Account Payables are $35.4 million (Q4 2025), $24.6 million (Q3 2025), and $45.0 million (Q2 2025).